<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10419">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971319</url>
  </required_header>
  <id_info>
    <org_study_id>Gliomark</org_study_id>
    <nct_id>NCT02971319</nct_id>
  </id_info>
  <brief_title>Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma</brief_title>
  <official_title>Exploratory Phase II Study in Patients After Treatment of High Grade Brain Tumors to Assess the Technical Performance of Tc-99m Tetrofosmin for Differentiation of Recurrence Versus Radiation Necrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proactina S.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ConsulTech GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>pharmtrace</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmathen SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Proactina S.A.</source>
  <brief_summary>
    <textblock>
      This study aims to assess the technical performance of Tc-99m tetrofosmin SPECT as compared
      to F-18 FDG PET for the differentiation of radiation necrosis from glioma relapse and to
      obtain estimates of diagnostic accuracy for Tc-99m tetrofosmin SPECT and F-18 FDG PET in an
      intra-individual comparison.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical performance of Tc-99m tetrofosmin SPECT</measure>
    <time_frame>assessed once within 3 weeks of inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Glioma (Diagnosis)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tc-99M-Tetrofosmin SPECT</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>F-18 FDG PET</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. confirmed high grade glioma (e.g., anaplastic astrocytoma, glioblastoma, anaplastic
             oligodendroglioma, or anaplastic oligoastrocytoma)

          2. being in follow-up for at least 3 months after completion of radiation therapy (with
             or without concurrent chemotherapy)

          3. inconclusive MRI results regarding the differentiation between recurrence and
             radiation necrosis

          4. willing and able to undergo all study procedures

          5. informed consent in writing (dated and signed)

        Exclusion Criteria:

          1. age: less than18 years

          2. if female, pregnant or breast feeding (females of child-bearing potential must use
             adequate contraception and must have a negative pregnancy test performed within 7
             days prior to inclusion into this study)

          3. contraindications for Tc-99m tetrofosmin

          4. contraindications for F-18 FDG

          5. close affiliation with the investigational site; e.g. first-degree relative of the
             investigator

          6. participating in another therapeutic clinical trial or has completed study
             participation in another therapeutic clinical trial within 5 days of enrolment into
             this trial

          7. having been previously enrolled in this clinical trial

          8. being mentally disabled

          9. mental conditions rendering the subject incapable to understand the nature, scope,
             and consequences of the trial

         10. Being clinically unstable or requiring emergency treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eva Levi, PhD</last_name>
    <phone>+302106622386</phone>
    <phone_ext>1052</phone_ext>
    <email>eva.levi@proactina.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Neurologie Mazarin Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Laigle-Donadey, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Országos Klinikai Idegtudományi Intézet (OKITI)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imre Fedorcsák, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Országos Onkológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>József Lövey, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pozitron-Diagnosztika Ltd.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Lengyel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scanomed Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Péter Szabó, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Kórház</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>László Landherr, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos- és Egészségtudományi Centrum</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judit Kocsis, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scanomed Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ildikó Garai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem, Általános</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>László Mangel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>November 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
